- Home
- BHC vs KARD Comparison
BHC vs KARD Comparison
Compare BHC & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHC | KARD |
|---|---|---|
| Founded | N/A | 2023 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 1996 | 2026 |
Fundamental Metrics
Financial Performance| Metric | BHC | KARD |
|---|---|---|
| Price | $6.06 | $14.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $7.50 | ★ $42.25 |
| AVG Volume (30 Days) | ★ 1.7M | 648.9K |
| Earning Date | 10-28-2026 | 11-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 423.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,724,000,000.00 | N/A |
| Revenue This Year | $6.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.33 | $12.23 |
| 52 Week High | $8.00 | $27.00 |
Technical Indicators
Market Signals| Indicator | BHC | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 41.56 |
| Support Level | $5.44 | $13.75 |
| Resistance Level | $6.31 | $22.81 |
| Average True Range (ATR) | 0.21 | 1.27 |
| MACD | 0.05 | 0.11 |
| Stochastic Oscillator | 67.72 | 63.41 |
Price Performance
Historical ComparisonAbout BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
About KARD Kardigan Inc. Common Stock
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.